Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

20 Pages (Click to Jump) V  « < 17 18 19 20   
 
  
Reply to this topic

PEB, PACIFIC EDGE BIOTECHNOLOGY LIMITED
Lizard
post Posted: Jun 3 2008, 01:36 PM
  Quote Post


Posts: 911
Thanks: 53


The notice says they became a substantial holder on 29 February. There do not seem to be much in the way of transactions on that date or for a few days prior. However, the preference shares converted 7:1 to 1.1m shares on that date, so perhaps they held the prefs up until then and they were not counted at the same ratio as actual conversion?

Otherwise, there have been the odd larger (500k) sized transactions in the last year - possibly they accumulated over a long period and only just triggered 5%.

 
plastic
post Posted: Jun 3 2008, 09:55 AM
  Quote Post


Posts: 10,533
Thanks: 306


Lizard, do you know how the ACC got their 5%? I doubt very much that it was on-market it just seems too illiquid.





--------------------
What did Uncle Mel do to us?
 
Lizard
post Posted: May 31 2008, 05:27 PM
  Quote Post


Posts: 911
Thanks: 53


Half year opening paragraph:
QUOTE
The half year to September 2007 has been strong as Pacific Edge moves closer to market realisation with its life saving cancer tests. The bladder cancer assay clinical trial is underway and the colorectal cancer assay, close behind it.


Fully year commentary:
QUOTE
The clinical trial for the detection of bladder cancer, using urine samples, will be carried out on nine sites in New Zealand.


Some advice to small companies; read your previous announcements and aim for continuity. Why, six months later, does it now appear that the "underway" clinical trial is just about to start?

Oh, and one other piece of unsolicited advice; underselling yourself can be fatal to future capital raising.

To manifest more specifically; given that the government announced fast-tracking of colo-rectal screening the day before, why was there absolutely NO mention of progress on the colorectal assay in the full year result??? rolleyes.gif

 
plastic
post Posted: Mar 10 2008, 03:21 PM
  Quote Post


Posts: 10,533
Thanks: 306


QUOTE
the $10-$12m market cap for PEB does seem quite low in comparison with the potential for their diagnostics. I hold a small quantity for interest, though am expecting it to be a fairly slow wait, as these things generally tend to drag out much longer to first revenues than is indicated.


Lizard, you are sooo right. Except with the way the small cap biotechs are at the moment, it is not the business development process you must look to for a value. It will be the PIPEs they sell to Roche and Pfizer etc that will set the price and for us if you are buying now, the profit.

And as you say, PEB is so low to be ridiculous. You mentioned your example which I am not familiar with but on the ASX the closest cousin PEB has is FER. Check out their bubble.



--------------------
What did Uncle Mel do to us?
 
Lizard
post Posted: Feb 19 2008, 08:01 PM
  Quote Post


Posts: 911
Thanks: 53


Actually, also of interest in this regard is the progress of Matritech who were the major US producer of the Bladderchek test. Matritech was expecting FY07 revenues of around $US15m, coming largely from this business. However, the company continued to report quarterly losses and the assets were recently sold to Inverness Medical Innovations for $US36m. Matritech has since filed for dissolution. The sale and dissolution was expected to realise $US10 - $US12m for shareholders.

Perhaps not terribly encouraging for my small investment in PEB. unsure.gif

 
Lizard
post Posted: Feb 19 2008, 07:44 PM
  Quote Post


Posts: 911
Thanks: 53


PEB has announced completion of a $5.2m raising - most of which had previously been allotted and announced at 13.7cps (plus a small amount to existing holders at 12.9cps). This is said to be sufficient cash to see the company through until launch of their first product, with first revenues "reasonably expected" to closely follow the completion of the bladder cancer trial in 12 months time. The company is also completing a trial for the colorectal cancer diagnostic and has several other products under development.

While I'm not an enthusiast about biotech stocks, the $10-$12m market cap for PEB does seem quite low in comparison with the potential for their diagnostics. I hold a small quantity for interest, though am expecting it to be a fairly slow wait, as these things generally tend to drag out much longer to first revenues than is indicated.

 
 


20 Pages (Click to Jump) V  « < 17 18 19 20

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING